Results 81 to 90 of about 1,560,419 (396)

SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions

Viruses, 2020
The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic infections to mild respiratory symptoms to the lethal form of COVID-19 which is ...
M. Uddin, F. Mustafa, T. Rizvi, T. Loney, H. Suwaidi, Ahmed H. Al-Marzouqi, A. K. Eldin, N. Alsabeeha, T. Adrian, Cesare Stefanini, N. Nowotny, A. Alsheikh-Ali, A. Senok   +12 more
semanticscholar   +1 more source

Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study

Frontiers in Immunology, 2022
Current vaccination strategies against influenza focus on generating an antibody response against the viral haemagglutination surface protein, however there is increasing interest in neuraminidase (NA) as a target for vaccine development. A critical tool
Marie-Clotilde Bernard, Joanna Waldock, Sylvie Commandeur, Lea Strauß, Claudia Maria Trombetta, Serena Marchi, Fan Zhou, Serge van de Witte, Peter van Amsterdam, Sammy Ho, Katja Hoschler, Vladimir Lugovtsev, Jerry P. Weir, Emanuele Montomoli, Rebecca J. Cox, Othmar G. Engelhardt, Damien Friel, Ralf Wagner, Thierry Ollinger, Sophie Germain, Hanna Sediri-Schön   +20 more
doaj   +1 more source

Pursuing equitable access to vaccines for the next epidemic [PDF]

arXiv, 2023
To mitigate the pandemic stemming from COVID-19, numerous nations have initiated extensive vaccination campaigns for their citizens since late 2020. While affluent countries have predominantly received vaccine allocations, fewer doses have been dispatched to nations with lower average incomes.
arxiv  

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]

, 2014
Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie, Hamers, Claude, Hudelet, Pascal, Nunes, Sandro Filipe, Palmarini, Massimo, Ratinier, Maxime, Shaw, Andrew   +6 more
core   +2 more sources

Outside in – inside out. Creating focus on the patient – a vaccine company perspective

Human Vaccines & Immunotherapeutics, 2018
Involving patients in the development of medicines and vaccines should result in benefits to patients. The vaccine recipient is usually a healthy person.
Denis Sohy, Isabelle Dusart, Philibert Goulet, Diane Visy, Luc Gasthuys, Tatjana Poplazarova, Thomas Breuer, Norman Begg   +7 more
doaj   +1 more source

Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa

Vaccines, 2020
Developing vaccine technology platforms to respond to pandemic threats or zoonotic diseases is a worldwide high priority. The risk of infectious diseases transmitted from wildlife and domestic animals to humans makes veterinary vaccination and animal ...
Omar Farnós, Esayas Gelaye, Khaled Trabelsi, Alice Bernier, Kumar Subramani, Héla Kallel, Martha Yami, Amine A. Kamen   +7 more
doaj   +1 more source

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

Viruses, 2021
The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve.
Sabari Nath Neerukonda, Russell Vassell, Sabrina Lusvarghi, Richard Wang, Fernando Echegaray, Lisa Bentley, Ann E. Eakin, Karl J. Erlandson, Leah C. Katzelnick, Carol D. Weiss, Wei Wang   +10 more
doaj   +1 more source

Generalized epidemic model incorporating non-Markovian infection processes and waning immunity [PDF]

, 2023
The Markovian approach, which assumes exponentially distributed interinfection times, is dominant in epidemic modeling. However, this assumption is unrealistic as an individual's infectiousness depends on its viral load and varies over time. In this paper, we present a Susceptible-Infected-Recovered-Vaccinated-Susceptible epidemic model incorporating ...
arxiv   +1 more source

The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors

Biotechnology Journal, 2015
The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors.
R. Felberbaum
semanticscholar   +1 more source

Roadblocks to translational challenges on viral pathogenesis. [PDF]

, 2013
Distinct roadblocks prevent translating basic findings in viral pathogenesis into therapies and implementing potential solutions in the clinic. An ongoing partnership between the Volkswagen Foundation and Nature Medicine resulted in an interactive ...
Deeks, Steven, Drosten, Christian, Picker, Louis, Subbarao, Kanta, Suzich, Joann   +4 more
core   +1 more source